MedTrace Logo

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2020-12-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Conditions

  • Paroxysmal Supraventricular Tachycardia (PSVT)

Interventions

DRUG

Etripamil

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

DRUG

Placebo

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Milestone Pharmaceuticals Inc.

    lead OTHER

Principal Investigators

  • Francis Plat · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-27
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02296190 on ClinicalTrials.gov